Cited by 176Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Open access

Ballantyne, Christie M., Davidson, Michael H., MacDougall, Diane E., Bays, Harold E., DiCarlo, Lorenzo A., Rosenberg, Noah L., Margulies, Janice, Newton, Roger S.·2013·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2013.05.050

Open this paper in CoChat — free account Open PDF

Abstract

Objectives The aim of this study was to assess the lipid-altering efficacy and safety of ETC-1002 in subjects with hypercholesterolemia. Background ETC-1002 is a small molecule that modulates pathways of cholesterol, fatty acid, and carbohydrate metabolism and may have therapeutic benefits in treating hypercholesterolemia and other cardiometabolic risk factors. Methods This multicenter, randomized, double-blind, placebo-controlled, parallel-group trial evaluated patients (n = 177) with elevated low-density lipoprotein cholesterol (LDL-C) (130 to 220 mg/dl), who were stratified by baseline triglycerides (not elevated [ Results ETC-1002 40, 80, and 120 mg lowered least-squares mean ± SE LDL-C levels by 17.9 ± 2.2%, 25.0 ± 2.1%, and 26.6 ± 2.2%, respectively, versus a reduction of 2.1 ± 2.2% with placebo (all, p Conclusions ETC-1002 significantly lowered LDL-C levels up to 27% across a broad range of baseline triglycerides and was generally safe and well tolerated. ETC-1002 has a novel mechanism of action and may be useful for reducing LDL-C. (A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides; NCT01262638).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.05.050

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
A comprehensive evaluation of the heparin–manganese precipitation procedure for estimating high density lipoprotein cholesterol
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,248
Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 734

Show all 27 references

Sorted by citations

Items 101–176 of 176

Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials
Venkatraman, S., Das, S., Eerike, M., Cherian, J. J., & Bagepally, B. S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03555-8 · Cited by 10
Recent developments in modulating atherogenic lipoproteins
White, C. R., Goldberg, D., & Anantharamaiah, G. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000216 · Cited by 10
Poststatin Lipid Therapeutics: A Review
Jia, X., Lorenz, P., & Ballantyne, C. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-32 · Cited by 11
Self-citation
Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain
Srivastava, R. A. K., Cornicelli, J. A., Markham, B. E., & Bisgaier, C. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00471 · Cited by 8
Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Atar, D., Langslet, G., & Tonstad, S. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0117 · Cited by 8
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemia
Jadhav, S. B., Amore, B. M., Bockbrader, H. N., Crass, R. L., Chapel, S. H., Sasiela, W. J., & Emery, M. G. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09864-w · Cited by 8
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease
Rajabian, A., McCloskey, A. P., Jamialahmadi, T., Moallem, S. A., & Sahebkar, A. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0005 · Cited by 7
Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review
Li, Y., Gao, H., Zhao, J., Ma, L., & Hu, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297854 · Cited by 8
The past, present and future of lipidlowering therapy
Najam, O., Lambert, G. C., & Ray, K. K. (2015) · Clinical Lipidology · doi:10.2217/clp.15.40 · Cited by 7
Bempedoic acid as a PPARα activator: New perspectives for hepatic steatosis treatment in a female rat experimental model
Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.001 · Cited by 7
Efficacy and Safety of Bempedoic Acid to Prevent Cardiovascular Events in Individuals at Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized-Control Trials
Mohan, G. V. K., Chenna, V. S. H., Tirumandyam, G., Mian, A. R., Rashid, A., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.38662 · Cited by 7
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Bempedoic acid: Review of a novel therapy in lipid management
Delevry, D., & Gupta, E. K. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa352 · Cited by 7
Bempedoic acid for the treatment of hypercholesterolemia
Yang, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1782744 · Cited by 6
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology
Patti, G., Cavallari, I., Cesaro, A., Gragnano, F., Riva, L., Fimiani, F., Cuccia, C., Fresco, C., Calabrò, P., Leonardi, S., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107137 · Cited by 6
Untangling the relationship between bempedoic acid and gout: results from a systematic literature review
Alunno, A., Carubbi, F., Campanozzi, E., Bellisario, F., Schoones, J. W., Mariani, F. M., Ruscio, E. D., Altieri, P., & Ferri, C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1234601 · Cited by 6
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 8
El ácido bempedoico como activador PPARα: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra
Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.09.004 · Cited by 6
Targeting Low-Density Lipoprotein AND Dysmetabolism in Type 2 Diabetes Mellitus
Goldberg, R. B. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303171 · Cited by 5
Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data
Li, B., Zhang, J., Huang, A., Chen, Y., & Wei, Q. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132305 · Cited by 7
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls, S. J., & Nelson, A. J. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362644 · Cited by 6
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 5
Empleo del ácido bempedoico en los pacientes con dislipemia. Una aproximación práctica
Escobar, C., Barrios, V., Ariza, A., Campuzano, R., Martínez, J. M. G., & Mostaza, J. M. (2021) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(21)00005-4 · Cited by 5
AMP-Activated Protein Kinase: A Metabolic Stress Sensor in the Heart
Pelosse, M., Tokarska-Schlattner, M., & Schlattner, U. (2015) · Springer eBooks · doi:10.1007/978-3-319-15263-9_10 · Cited by 4
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
Wójcik, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1376570 · Cited by 4
Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
Natale, F., Molinari, R., Franzese, R., Mollo, N., & Cimmino, G. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3020024 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
SLC12A3 variants modulate LDL cholesterol levels in the Mongolian population
An, C., Zhang, K., & Su, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0413-x · Cited by 4
A Newly Approved Cholesterol Drug Joins the Lipid-Lowering Arsenal: Bempedoic Acid
Furer, J., Popova, O., & Plakogiannis, R. (2020) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2020.08.022 · Cited by 5
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
Self-citation
Bempedoic Acid: A Contemporary Review of Its Pharmacology, Efficacy, and Safety Profile, Including Recent Data from the CLEAR Outcomes Clinical Trial
Park, J. K., Balarbar, N., & Agarwala, A. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01911-9 · Cited by 3
Clinical efficacy and safety outcomes of bempedoic acid: An updated systematic review and meta-analysis after CLEAR Outcomes trial
Bhandari, A., Oli, P. R., Shrestha, D. B., Dawadi, S., Pathak, B. D., Bhandari, M., Sedhai, Y. R., Basnet, B., Regmi, L., Singh, A., et al. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100116 · Cited by 3
How Will Our Practice Change After the CLEAR Outcomes Trial?
Abrahams, T., Nelson, A. J., & Nicholls, S. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01188-5 · Cited by 3
Bempedoinsäure – Wirkmechanismus und klinische Studien
Katzmann, J. L., & Laufs, U. (2020) · Aktuelle Kardiologie · doi:10.1055/a-1142-7957 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Bempedoic Acid: A New Avenue for the Treatment of Dyslipidemia
Smith, W., Cheng-Lai, A., & Nawarskas, J. J. (2021) · Cardiology in Review · doi:10.1097/crd.0000000000000401 · Cited by 3
New Horizons in Lipid Management
Kane, J. P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.052 · Cited by 3
Paradoxical activation of SREBP1c and de novo lipogenesis by hepatocyte-selective ACLY depletion in obese micePreprint
Yenilmez, B., Kelly, M., Zhang, G., Wetoska, N., Ilkayeva, O., Min, K., Rowland, L. A., DiMarzio, C., He, W., Raymond, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.21.485183 · Cited by 3
Lipid and anti-inflammatory effects of bempedoic acid across treatment regimens: A harmonized meta-analysis of randomized trials
Alkayed, H. A., Rajesh, R., Shaikh, A., Martins, R., & Alrabadi, B. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.015 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Management of lipid abnormalities in metabolic syndrome
Fariduddin, M. M., & Naik, R. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00048-7 · Cited by 2
OS TIPOS DE TRATAMENTOS ATUALMENTE DISPONÍVEIS PARA DISLIPIDEMIA E CONTROLE DOS TRIGLICERÍDEOS
Nogueira, D. R., Melo, G. C. D. C., Silva, I. D. A. C. E., Moreira, L. E. P., Pedrosa, M. D. S. B., Cardinali, M. D. P., Peron, P. L. V., & Piazzi, R. G. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024264p13 · Cited by 2
Efficacy and Safety of Bempedoic Acid as a Treatment Option for Hyperlipidemia: A Systematic Review
Sharif, M. H., Orakzai, A. A., Khaleeque, M., Raza, S. S., Khan, O. S., Jan, M. H., Ahmed, A., & Arsalan, M. (2024) · Advances in Clinical Medical Research and Healthcare Delivery · doi:10.53785/2769-2779.1198 · Cited by 1
Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials
Goyal, A., Shah, S., Dahal, K., Changez, M. I. K., Tariq, M. D., Zuhair, V., Shamim, U., Abbasi, H. Q., Shrestha, A. B., Sah, R., et al. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000302 · Cited by 2
Efficacy and Safety of Bempedoic Acid for Prevention of Adverse Cardiovascular Events and Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yasmin, F., Najeeb, H., Moeed, A., Ali, E., Umar, M., Ullah, I., Shah, N. P., & Alraies, M. C. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001715 · Cited by 2
Missing Regulation Between Genetic Association and Transcriptional Abundance for Hypercholesterolemia Genes
Hakim, A., Connally, N. J., Schnitzler, G. R., Cho, M., Jiang, Z. G., Sunyaev, S. R., & Gupta, R. M. (2025) · Genes · doi:10.3390/genes16010084 · Cited by 3
Highlights of the Year in JACC 2013
DeMaria, A. N., ADLER, E. D., Bax, J. J., Ben‐Yehuda, O., Feld, G. K., Greenberg, B., Hall, J. L., Hlatky, M. A., Lew, W. Y. W., Lima, J. A. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.002 · Cited by 2
Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease
Almarzooq, Z., & Singh, P. (2016) · InTech eBooks · doi:10.5772/64762 · Cited by 2
The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
Thanassoulis, G., Grégoire, J. C., & Pearson, G. J. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.03.003 · Cited by 2
Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease
Noh, S., Mai, K., Shaver, M., Yong, S., MOSTAGHIMI, M., Oh, G., & Radwan, M. M. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.12.011 · Cited by 3
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
Translating Lipoprotein Genetics Into New Therapies
Hegele, R. A. (2026) · Circulation Research · doi:10.1161/circresaha.126.328828 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol
Korzh, O. (2020) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2020.101217 · Cited by 1
Zmiany Na Rynku Pracy Miasta Bydgoszczy W Latach 2000-2014 = Changes In The Labour Market Of The City Of Bydgoszcz In The Years 2000-2014
Barwińska-Szczutkowska, G., Harłoziński, K., & Szczutkowski, J. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.5281/zenodo.49756
Emerging molecular strategies for management of dyslipidemias
Kane, J. P., & Malloy, M. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000243
Prevention of Murine Atherosclerosis with Bempedoic Acid
Samsoondar, J. P. (2016) · Scholarship@Western (Western University)
Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?
Samanta, B. (2019) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0039-1697239 · Cited by 1
Desarrollo clínico de ácido bempedoico: estudios fase 2 y fase 3
Lekuona, I., & Pintó, X. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.005
Bempedoic Acid
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00022-4
Genetic Risk Stratification Will Enhance Primary Prevention of Coronary Artery Disease
Roberts, R., & Acuna, E. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.1.4063
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant
Doggrell, S. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242259
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Çaklılı, Ö. T., Rizzo, M., & Cesur, M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611290763240126045433
Bempedoic acid - a practical review
Nussbaumerová, B. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.020
Bempedoic Acid in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
Samajdar, S. S., Sarkar, S., Chakraborty, S., Sarkar, D., Ghosh, S., Banerjee, S., Biswas, K., Pal, J., Chatterjee, N., Bandyopadhyay, S. K., et al. (2025) · Medical Journal of Dr D Y Patil Vidyapeeth · doi:10.4103/mjdrdypu.mjdrdypu_576_24
Novel Lipid-Lowering Agents
Ahmad, Z., & Garg, A. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_30
Additional file 3 of Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336387
Additional file 1 of Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis
Wang, X., Zhang, Y., Tan, H., Wang, P., Zha, X., Chong, W., Zhou, L., & Fang, F. (2020) · Figshare · doi:10.6084/m9.figshare.12799011
Additional file 1 of Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336375
Additional file 2 of Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336381
Aerobic exercise reduces lipid accumulation via ACLY-mediated metabolic remodeling to alleviate cardiac remodeling
Zhang, G., Yang, Z., Zhang, M., Zhang, D., Gao, J., Wang, L., Zheng, X., Wang, K., Chao, R., Lv, X., et al. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124590
Bempedoic Acid: From Guidelines to the Real World
Zimodro, J. M., & Gouni‐Berthold, I. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.3.381
The AMPK signaling pathway in cell metabolism and human diseases
Zhang, Z., Gu, Y., He, H., Qiao, S., Shao, Y., 龙先铭, Huang, J., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02790-6

Authors: Ballantyne, C. M., Davidson, M. H., MacDougall, D. E., Bays, H. E., DiCarlo, L. A., Rosenberg, N. L., Margulies, J., & Newton, R. S.
Affiliations: Houston Methodist (US)
University of Chicago (US)
Esperion Therapeutics (United States) (US)
Louisville Metabolic and Atherosclerosis Research Center (US)
Corresponding author: Ballantyne, Christie M.
ORCID: Ballantyne, Christie M.
Davidson, Michael H.
MacDougall, Diane E.
Bays, Harold E.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2013-09
Volume: 62
Issue: 13
Pages: 1154-1162
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2013.05.050
OpenAlex: W201469966
Semantic Scholar: 65747388e68ae65eab0dfc122080ea1ceeab19d5
Cited by: 175
References: 27
Citations by year: 2026: 6 · 2025: 4 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 18 · 2020: 26 · 2019: 14 · 2018: 13 · 2017: 7 · 2016: 19 · 2015: 10 · 2014: 10 · 2013: 2
FWCI: 13.48
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 388 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: American Heart Association
Amgen
Bristol-Myers Squibb
AstraZeneca
GlaxoSmithKline
Sanofi
Amarin Corporation
Esperion Therapeutics
National Institutes of Health
U.S. Food and Drug Administration
Genentech
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: hypercholesterolemia, LDL cholesterol lowering, ATP citrate lyase, AMPK, lipid-lowering therapy, non-HDL cholesterol, apolipoprotein B, LDL particle number, triglycerides, cardiometabolic risk factors, drug safety and tolerability, dose-response relationship, statin-resistant hypercholesterolemia
MeSH terms: Aged, Hypolipidemic Agents, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Female, Humans, Hypercholesterolemia, Male, Middle Aged, Risk Factors, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks